Monsanto's $47 billion bid to buy Swiss rival Syngenta has fallen through, the U.S. company said on Wednesday.» Read More
Reynolds American and Lorillard are agreeing a complex merger that will reshape Big Tobacco, bringing together the two biggest US operators.
For some corporate founders, the market's rally this year has meant a fortune. Who's gained the most?
The value of potential takeovers yanked from the market is at its highest level since the height of the global credit crisis in 2008.
There will likely be more food industry mergers in the months ahead, analysts say. Here's why.
There is market rumor and speculation that Dublin-based, U.K.-listed pharma company Shire is a takeover target.
Apple's $3 billion acquisition of Beats is not a needle mover for the stock, but it makes sense, CNBC's Jim Cramer said.
Global companies paid out $228.4 billion in dividends in the first quarter this year, but Russian company dividends more than halved.
Kellogg shares are up roughly 10 percent this year amid speculation Buffett might acquire the company, but not everyone is sure it's a good idea.
AT&T is in active talks to buy satellite-TV provider DirecTV and may complete a deal in the next few weeks, according to media reports.
Pfizer has been rebuffed more often than a particularly unlucky suitor in a romance novel by coy AstraZeneca.
Cheetah Mobile's shares spiked in their market debut, valuing the Chinese security software maker at about $2.2 billion.
Ford says it will buy back up to about 116 million shares of company stock worth about $1.8 billion.
DirecTV is working with advisers including Goldman Sachs to weigh a possible merger with AT&T, according to Dow Jones, which cited sources.
Two big succession stories dominated the headlines Thursday morning, and to CNBC's Jim Cramer, they couldn't be more different.
While it seems that kids are playing with touchscreens more than toys, Lego Group is confident that the building-blocks will remain relevant forever.
Pfizer's $100 billion offer to acquire British rival AstraZeneca is an effort to achieve an "efficient" tax structure, the company said.